Surgery Grand Rounds
August 14, 2013
Duke North – Room 2002
Surgical Grand Rounds
7:00 – 8:00 a.m.
“Team STEPPS Implementation for General Surgery”
Douglas S. Tyler, M.D.
Professor of Surgery
Chief, Division of Surgical Oncology
Chief, Surgical Services, Durham VA Medical Center
Director, Melanoma Program, Duke Cancer Institute
Director, Surgical Oncology Clinical Operations, Duke University Health System
Vice Chairman, Department of Surgery
Judy Milne, RN, MSN, CPHQ, CPPS
Patient Safety Officer
Duke University Hospital
Beverly King, RN, BSN, CNOR
Operations, General Service
Duke University Hospital
Surgical Case Conference
8:00 – 9:00 a.m.
Moderator: Bryan Clary, M.D.
Presenter Disclosure of Financial Relationships: Dr. Tyler discloses that he is an Advisory Board Member at Genetech and Amgen; a Speaker for Novartis; a Principal Investigator for Schering-Plough and Bristol-Myers Squibb; and a Consultant for AGTC, but no financial relationships relative to the content presented and no personal/financial relationships to disclose which are relative to this activity. Dr. Clary, Judy Milne, RN, MSN, CPHQ, CPPS, and Beverly King, RN, BSN, CNOR indicate no personal or financial relationships to disclose which are relative to this activity.
RSS Activity Medical Director(s) Disclosure: Dr. Ranjan Sudan has no personal/financial relationships to disclose which are relative to this activity.
---Global Learning Objectives---
1. Review and discuss new advances in general surgery;
2. Present and discuss case studies, protocols, treatment guidelines and surgical/pathology report appropriate to General Surgery practice;
3. Review and discuss clinical research findings and other evidence from pertinent literature.
The Duke University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
---Unapproved Use Disclosure---
Duke School of Medicine requires CME faculty (speakers) to disclose to the attendees: 1) When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (Not FDA approved) ; and 2) Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and /or unsupported opinion. Faculty at this event may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education, and is not intended to promote off-label use of these medications. If you have any questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The Duke University School Of Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
In order to receive CME Credit, learners must sign in at the beginning of this event.